AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05566691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thought reevaluation
Description: Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts.
Study NCT05566691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thought reevaluation + Mood induction
Description: Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
Study NCT04597359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05994742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin is commonly used in the first-line management of paediatric tuberculosis, and is approved by the FDA (ID: 2862628) and the EMA (EMA/31710/2020).
Study NCT05994742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin is a macrolide antibiotic, and is approved for use in children by the FDA (ID: 3263750) and EMA (EMA/2872/2021).
Study NCT05994742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid is an antibiotic commonly used in the firstline treatment of tuberculosis, and as tuberculosis prophylaxis.
Study NCT05994742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine Hydrochloride
Description: Pyridoxine is a form of vitamin B6 used to prevent peripheral neuropathy among children receiving isoniazid.
Study NCT05994742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Friendship Bench
Description: The Friendship Bench was developed in Zimbabwe as a low-cost psychological intervention utilising problemsolving therapy (delivered by trained lay workers) and peer-to-peer support to address depression and other common mental disorders. There is a strong evidence base for its use in urban LMIC settings. Peer support groups meet every 1-2 weeks and focus on communal problem solving, and establishing income-generation activities (such as making bags).
Study NCT05994742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care for Child Development
Description: Care for Child Development is a UNICEF package that helps families build stronger relationships and solve problems in caring for the child at home, through play and communication activities to stimulate children, through a series of age-appropriate interactive modules delivered by a lay worker using 'flash' cards. It has been used in other African contexts and has good acceptability.
Study NCT05994742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational and behaviour-change modules
Description: Educational and behaviour-change messages around better nutrition; play for children with SAM; stigma,HIV and gender-based violence; financial planning; causes of SAM; and health-seeking behaviours. These have been developed with caregivers affected by SAM in a previous study, through a series of codesign workshops, ensuring these are contextually relevant.
Study NCT05994742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reformulated Ready to Use Therapeutic Food
Description: A reformulated product designed to improve outcomes for children who have severe acute malnutrition.
Study NCT05994742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: All children will receive care according to WHO guidelines, which includes standard RUTF and any other medications required.
Study NCT05994742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: All children will receive care according to WHO guidelines, which includes standard RUTF and any other medications required.
Study NCT05650632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383
Description: Intravenous Infusion
Study NCT06051032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon thrombectomy
Description: A specialized catheter with an inflatable balloon at the tip is inserted over a guidewire, previously inserted through the sheath, and advanced to the location of the clot within the blood vessel. The catheter is positioned precisely using fluoroscopic guidance or other imaging modalities. Once positioned, the balloon is inflated, creating pressure against the clot and effectively removing or dislodging it from the vessel walls.
Study NCT06051032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thromboaspiration system
Description: The thromboaspiration catheter is carefully guided to the site of the clot within the blood vessel. Once positioned, the suction mechanism is activated, creating a vacuum effect. The catheter gently aspirates or suctions the clot, gradually removing it from the vessel walls. The procedure is performed under fluoroscopic guidance or other imaging modalities to ensure accurate placement of the catheter and successful clot aspiration.
Study NCT06365437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product
Study NCT06365437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression
Study NCT06365437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression
Study NCT06365437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression
Study NCT06365437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression
Study NCT06365437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression
Study NCT06365437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression
Study NCT06365437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Standard of Care induction therapy in solid organ transplantation
Study NCT05563857 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME Precision Nutrition Program
Description: Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
Study NCT05563857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME-designed condition-based supplements
Description: Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
Study NCT06348849 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy
Description: Wavelength 980nm (SmartM, Lasotronix, Poland)
Study NCT06348849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanosilver fluoride
Description: Optimized synthesis of Nanosilver Fluoride
Study NCT06334952 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: transcranial direct current stimulation
Description: Research MRI includes 3D-T1 weighted MRI (3D-T1), diffusion MRI (dMRI), resting-state functional MRI (rsfMRI).
Study NCT05531643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Cefaly Dual (R)
Description: Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A biphasic rectangular wave will be delivered for a maximum of 20 minutes at a maximum amplitude of 16mA. Participant may halt amplitude before it reaches maximum amplitude. The device has previously been cleared by the FDA for use in migraine patients.
Study NCT05531643 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Cefaly Dual (R)
Description: Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A 1Hz wave will be delivered for 20 minutes at 1mA.
Study NCT06377566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin will be administered at 1.2 mg/kg IV on days 1 and 15 of each 28-day cycle
Study NCT06377566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 25 mg/m\^2 IV
Study NCT06377566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine 6 mg/m\^2 IV
Study NCT06377566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine 375 mg/m\^2 IV on days 1 and 15 of each 28-day cycle
Study NCT06377566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV (flat) on day 1
Study NCT06377566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 IV (days 1 an
Study NCT06377566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinblastine 6 mg/m\^2 IV
Study NCT06377566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT scan
Description: After 2 cycles of therapy, patients will undergo FDG-PET/CT scan
Study NCT04651088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium citrate
Description: Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
Study NCT04651088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium citrate
Description: Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
Study NCT04651088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: 650mg tabs. Take 3 tabs twice daily.
Study NCT04651088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium bicarbonate
Description: 650mg tabs. Take 3 tabs twice daily.
Study NCT04651088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Litholyte
Description: One packet is taken with 170ml of water. Two packets daily.
Study NCT04597359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04597359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04651088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Litholyte
Description: One packet is taken with 170ml of water. Two packets daily.
Study NCT04597359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04597359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04597359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinecatechins
Description: Given PO
Study NCT05045807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat with added nitrate
Description: Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with the sodium nitrate and nitrite as an additive.
Study NCT05045807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat with added nitrate plus vegetables
Description: The same intervention as of intervention meat with added nitrate consumed together with mixed vegetables.
Study NCT05053334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab Prefilled Syringe
Description: 150mg/ml of Omalizumab prefilled syringe
Study NCT05053334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab Prefilled Syringe
Description: 150mg/ml of Omalizumab prefilled syringe
Study NCT05456464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki is applied touching the energy centers of the body (chakras). There are seven main and many small chakras on a body. Chakras are located on the front and back sides of the body in a vertical line that runs along the middle of the body in humans. A complete Reiki therapy includes all the chakras and organs.
Study NCT05352334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: self-report Emotional Intelligence test (SSCEIT)
Description: The participants fulfilling the inclusion criteria will be selected from above mentioned different government and private universities. The total number of participants in data collection procedure will be 44. Informed consent will be taken from all the students and self-administered questionnaire will be distributed to students for data collection procedure. The emotional intelligence and physical activity will be measured and collected through Schutte self-report Emotional Intelligence test (SSCEIT) and international physical activity questionnaire. The questionnaires for physical activity will consist of 12 questions and for SSCEIT consist of 33 questions. Emotional intelligence will be measured by schutte self-report emotional intelligence scale and physical activity will be measured by international physical activity questionnaire.
Study NCT04651088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crystal Lite
Description: The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
Study NCT05128786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCT301-38
Description: Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT301-38. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single or multiple dose of CCT301-38 via intravenous injection.
Study NCT05311176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-131
Description: IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.
Study NCT05311176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus Paclitaxel
Description: Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.
Study NCT05311176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered every 3 weeks (Q3W) starting on Day 1 until disease progression or treatment discontinuation.
Study NCT05432596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-1777 2.0% w/w
Description: ATI-1777 topical solution 2.0% w/w
Study NCT04651088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crystal Lite
Description: The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
Study NCT05432596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-1777 1.0% w/w
Description: ATI-1777 topical solution 1.0% w/w
Study NCT05432596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-1777 0.5% w/w
Description: ATI-1777 topical solution 0.5% w/w
Study NCT05432596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle topical solution
Study NCT05740631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocaliva
Description: Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.
Study NCT05740631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
Study NCT04880629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline condition
Description: In the baseline sleep condition, participants are instructed not to restrict their sleep on the night before completing an oral glucose tolerance test (OGTT). Participants are prescribed sleep-wake timings based on their preferred and averaged sleep durations measured over 2 weeks using a wearable sleep tracker. Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
Study NCT06645665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RSV Vaccine (IN006)
Description: Formulation for injection
Study NCT06645665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT04816955 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary recommendations
Description: Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations
Study NCT04816955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary recommendations
Description: Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations
Study NCT05092009 — intervention group
Intervention type: OTHER
Intervention: Tissue and blood
Description: Tissue and blood will be derived from patient during a standard of care procedure
Study NCT05560659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA
Description: Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Numerous retrospective series initially demonstrated high clinical activity and limited normal tissue toxicity using PSMA-617 and PSMA-I\&T, which are the most advanced small molecule inhibitors of PSMA, radiolabelled with 177Lu
Study NCT05786235 — intervention group
Intervention type: OTHER
Intervention: Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
Description: Patients will be enrolled in the study during the first trimester of gestation or later, if the diagnosis of APS is made during pregnancy followed by clinical practice. During the quarterly visits scheduled by clinical practice, the following will be collected relevant clinical information and the additional biological samples for analysis of serum levels of sFlt-1 and PlGF. A follow-up postpartum visit is scheduled by clinical practice at 6 weeks after completion of delivery.
Study NCT05786235 — intervention group
Intervention type: OTHER
Intervention: Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
Description: Patients will be enrolled during the performance of prenatal diagnosis, routinely chosen by the patient, at which the relevant clinical information and the additional biological sample . Collection of biological material in the 2nd and 3rd TM of gestation will take place at occasion of the routinely scheduled ultrasound scans . A postpartum follow-up visit is scheduled by clinical practice at 6 weeks after the completion of delivery.
Study NCT05848713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.~Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement.
Study NCT04651088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Bicarbonate
Description: 20 mEq tablets, one tablet twice daily
Study NCT04651088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Bicarbonate
Description: 20 mEq tablets, one tablet twice daily
Study NCT04799899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted MBCT
Description: The adapted MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health.
Study NCT04799899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Health Enhancement
Description: The cardiac health enhancement control group will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will learn about depression and cardiac health.
Study NCT05942417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echoguided percutaneous neuromodulation plus exercise
Description: This group is taking the EPNM and the exercise program
Study NCT05942417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strength program
Description: This group is taking the exercise program